Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Feb;51(2):219–228. doi: 10.1038/bjc.1985.32

Factors influencing the chemosensitization of melphalan by misonidazole.

V S Randhawa, F A Stewart, J Denekamp, M R Stratford
PMCID: PMC1977037  PMID: 3966979

Abstract

The effect of melphalan alone or combined with various schedules of misonidazole (MISO) has been tested on a murine fibrosarcoma. The tumoricidal effect has been determined using the growth delay assay. Large single doses (500-1000 mgkg-1) of MISO enhanced the anti-tumour effect of melphalan, especially at high melphalan doses. This was accompanied by a drop in body and tumour temperature and an increase in the melphalan half-life. The MISO-induced hypothermia was prevented in one experiment by keeping the mice in an ambient temperature of 35 degrees C for 3 h. This reduced the exposure to melphalan but did not diminish the cytotoxic effect of the drug combination. Chronic administration of MISO for an 8 h period gave no enhancement of melphalan damage, whether melphalan was given half-way through or at the end of the period of dosing. It seems that a threshold tumour concentration of MISO, in excess of 70 micrograms g-1, is needed for enhancement of melphalan cytotoxicity; prolonged exposures to very low doses are ineffective.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  2. Clutterbuck R. D., Millar J. L., McElwain T. J. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts. Am J Clin Oncol. 1982 Feb;5(1):73–78. [PubMed] [Google Scholar]
  3. Dische S., Saunders M. I., Flockhart I. R., Lee M. E., Anderson P. Misonidazole-a drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):851–860. doi: 10.1016/0360-3016(79)90070-1. [DOI] [PubMed] [Google Scholar]
  4. Hall E. J., Miller R., Astro M., Rini F. The nitroimidazoles as radiosensitizers and cytotoxic agents. Br J Cancer Suppl. 1978 Jun;3:120–123. [PMC free article] [PubMed] [Google Scholar]
  5. Hinchliffe M., McNally N. J., Stratford M. R. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Br J Cancer. 1983 Sep;48(3):375–383. doi: 10.1038/bjc.1983.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hirst D. G., Brown J. M. The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):639–642. doi: 10.1016/0360-3016(82)90702-7. [DOI] [PubMed] [Google Scholar]
  7. Martin W. M., McNally N. J., De Ronde J. Enhancement of the effect of cytotoxic drugs by radiosensitizers. Br J Cancer. 1981 Jun;43(6):756–766. doi: 10.1038/bjc.1981.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McNally N. J., Hinchliffe M., de Ronde J. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole. Br J Cancer. 1983 Aug;48(2):271–278. doi: 10.1038/bjc.1983.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Millar B. C. Hypoxic cell radiosensitizers as potential adjuvants to conventional chemotherapy for the treatment of cancer. Biochem Pharmacol. 1982 Aug 1;31(15):2439–2445. doi: 10.1016/0006-2952(82)90051-x. [DOI] [PubMed] [Google Scholar]
  10. Randhawa V. S., Stewart F. A., Denekamp J. Chemosensitization of mouse tumors by misonidazole. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):671–674. doi: 10.1016/0360-3016(82)90710-6. [DOI] [PubMed] [Google Scholar]
  11. Sheldon P. W., Batten E. L., Adams G. E. Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds. Br J Cancer. 1982 Oct;46(4):525–531. doi: 10.1038/bjc.1982.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Siemann D. W. Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):1029–1034. doi: 10.1016/0360-3016(82)90172-9. [DOI] [PubMed] [Google Scholar]
  13. Stephens T. C., Courtenay V. D., Mills J., Peacock J. H., Rose C. M., Spooner D. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer. 1981 Apr;43(4):451–457. doi: 10.1038/bjc.1981.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stratford I. J., Adams G. E. The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man. Br J Radiol. 1978 Sep;51(609):745–746. doi: 10.1259/0007-1285-51-609-745. [DOI] [PubMed] [Google Scholar]
  15. Twentyman P. R., Workman P. An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer. 1983 Feb;47(2):187–194. doi: 10.1038/bjc.1983.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Twentyman P., Workman P. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer. 1982 Mar;45(3):447–455. doi: 10.1038/bjc.1982.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Workman P. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol. 1980;5(1):27–37. doi: 10.1007/BF00578559. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES